MétaCan
Menu
Back to cohort
Record W4404888857 · doi:10.1002/cncr.35612

Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

2024· article· en· W4404888857 on OpenAlexaff
Alan H. Bryce, Neeraj Agarwal, Himisha Beltran, Maha Hussain, Oliver Sartor, Neal D. Shore, Emmanuel S. Antonarakis, Andrew J. Armstrong, Jérémie Calais, Michael A. Carducci, Tanya B. Dorff, Jason A. Efstathiou, Martin Gleave, Leonard G. Gomella, Celestia Higano, Thomas A. Hope, Andrei Iagaru, Alicia K. Morgans, David S. Morris, Michael J. Morris, Daniel P. Petrylak, Robert E. Reiter, Matthew B. Rettig, Charles J. Ryan, Scott B. Sellinger, Daniel E. Spratt, Sandy Srinivas, Scott T. Tagawa, Mary‐Ellen Taplin, Evan Y. Yu, Tian Zhang, Rana R. McKay, Phillip J. Koo, E. David Crawford

Bibliographic record

VenueCancer · 2024
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsUniversity of British Columbia
FundersNational Cancer InstituteNational Center for Advancing Translational SciencesAstraZenecaBayer HealthCareU.S. Department of Defense
KeywordsMedicineProstate cancerClinical trialConsensus conferenceCancerEvidence-based medicineIntensive care medicineOncologyGynecologyMedical physicsAlternative medicineInternal medicinePathology

Abstract

fetched live from OpenAlex

Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.221
metaresearch head score (Gemma)0.292
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.221
Threshold uncertainty score0.961

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.2210.292
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0030.009
Bibliometrics0.0140.006
Science and technology studies0.0040.003
Scholarly communication0.0090.008
Open science0.0100.014
Research integrity0.0140.018
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.077
GPT teacher head0.415
Teacher spread0.338 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCancerSame topicProstate Cancer Treatment and ResearchFrench-language works237,207